Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Genes, Erbb-2”

127 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 127 results

Post-approval studies (Phase 4)Ended earlyNCT05183828
What this trial is testing

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more
University of Washington 62
Testing effectiveness (Phase 2)Study completedNCT06083662
What this trial is testing

Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers

Who this might be right for
Metastatic CancerHER2 Gene Mutation
Korea University Guro Hospital 42
Not applicableTemporarily pausedNCT02993068
What this trial is testing

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Who this might be right for
BARD1 Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+12 more
M.D. Anderson Cancer Center 5,200
Large-scale testing (Phase 3)Study completedNCT00047255
What this trial is testing

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 263
Early research (Phase 1)Study completedNCT01265927
What this trial is testing

A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer

Who this might be right for
Breast Neoplasms
Indiana University 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT06136897
What this trial is testing

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Who this might be right for
Malignant Solid Neoplasm
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)UnknownNCT03638648
What this trial is testing

Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 80
Testing effectiveness (Phase 2)Study completedNCT03365882
What this trial is testing

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Who this might be right for
Colon AdenocarcinomaERBB2 Gene AmplificationRectal Adenocarcinoma+16 more
SWOG Cancer Research Network 240
Not applicableUnknownNCT04365790
What this trial is testing

Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma

Who this might be right for
Breast Cancer
Hellenic Cooperative Oncology Group 500
Not applicableStudy completedNCT01633203
What this trial is testing

Observational Study of Perioperative Chemotherapy in Gastric Cancer

Who this might be right for
Gastric Cancer
Grupo Oncologico Cooperativo Chileno de Investigation 61
Early research (Phase 1)Study completedNCT02260661
What this trial is testing

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Who this might be right for
Advanced Solid MalignanciesBreast Cancer - ER+, HER2 -Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
AstraZeneca 20
Testing effectiveness (Phase 2)UnknownNCT04215159
What this trial is testing

Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor

Who this might be right for
HER-2 Protein OverexpressionHER-2 Gene Amplification
Jin-Hee Ahn 42
Not applicableStudy completedNCT00897299
What this trial is testing

Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy

Who this might be right for
Breast CancerEstrogen ReceptorHer-2+1 more
Eastern Cooperative Oncology Group 900
Testing effectiveness (Phase 2)Study completedNCT05054374
What this trial is testing

Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Who this might be right for
Breast CancerBreast Cancer Stage IVHER2-negative Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 6
Large-scale testing (Phase 3)Active Not RecruitingNCT05048797
What this trial is testing

Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 454
Early research (Phase 1)UnknownNCT04764084
What this trial is testing

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Who this might be right for
HER2-negative Breast CancerGastric AdenocarcinomaCholangiocarcinoma+1 more
Peking University Cancer Hospital & Institute 52
Early research (Phase 1)Ended earlyNCT04182516
What this trial is testing

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences 52
Early research (Phase 1)Active Not RecruitingNCT04288089
What this trial is testing

H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Who this might be right for
Receptors, EstrogenGenes, Erbb-2Breast Neoplasms
Eisai Inc. 31
Early research (Phase 1)Not Yet RecruitingNCT07436858
What this trial is testing

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer (NSCLC)HER2 ExpressionHER2 Gene Mutation
The Netherlands Cancer Institute 20
Testing effectiveness (Phase 2)UnknownNCT06383533
What this trial is testing

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

Who this might be right for
Bile Duct Adenocarcinoma Non-ResectableHER2 Gene Mutation
Zhejiang Cancer Hospital 28
Next Page